2 active not recruiting, 2 completed, 2 terminated, 1 no longer available. 4 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Completed 2, Terminated 2 |
| Phase 2 | 3 | Active not recruiting 2, Terminated 1 |
Follow Miransertib: new trials by email Literature Review of Miransertib trials Research Report on Miransertib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| MK-7075 (Miransertib) in Proteus Syndrome MK-7075 (miransertib) - Proteus Syndrome | Phase 2 | Active not recruiting | National Human Genome Research Institute (NHGRI) | 38 | 2022-05-20 | 2026-07-17 |
| A Study of the Safety and Tolerability in Participants With PIK3CA-related Overgrowth Spectrum or Proteus Syndrome Who Are Being Treated With Miransertib (MK-7075) in Other Studies (MK-7075-006) Miransertib - PIK3CA-Related Overgrowth Spectrum (PROS)/Proteus Syndrome (PS) | Phase 2 | Active not recruiting | Merck Sharp & Dohme LLC | 60 | 2021-11-02 | 2025-02-07 |
| Study of Miransertib (MK-7075) in Participants With PIK3CA-related Overgrowth Spectrum and Proteus Syndrome (MOSAIC) (MK-7075-002) Miransertib - PIK3CA-Related Overgrowth Spectrum (PROS)/Proteus Syndrome | Phase 1 / Phase 2 | Terminated | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | 50 | 2017-05-16 | 2023-04-13 |
| Dose Finding Trial of MK-7075 in Children and Adults With Proteus Syndrome MK-7075 (miransertib) - Proteus Syndrome | Phase 1 | Completed | National Human Genome Research Institute (NHGRI) | 6 | 2015-11-16 | 2022-06-30 |
| Open-label Phase 1b Study of ARQ 092 in Combination With Anastrozole ARQ 092 + carboplatin + paclitaxel (Closed), ARQ 092 + paclitaxel (Closed), ARQ 092 + anastrozole - Solid Tumors, Ovarian Cancer | Phase 1 | Terminated | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | 41 | 2015-06-09 | 2020-09-30 |
| Phase 1 Dose Escalation Study of ARQ 092 in Adult Subjects With Advanced Solid Tumors and Recurrent Malignant Lymphoma ARQ 092 - Solid Tumor, Malignant Lymphoma | Phase 1 | Completed | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | 120 | 2011-11-01 | 2017-10-23 |
| Expanded Access to Provide ARQ 092 for the Treatment of Overgrowth Diseases and/or Vascular Anomalies ARQ 092 - Proteus Syndrome, PIK3CA-Related Overgrowth Spectrum (PROS) | No longer available | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | 2021-08-06 |
Congenital Abnormalities (3) · Hereditary Sensory and Autonomic Neuropathies (3) · Proteus Syndrome (3) · Endometrial Neoplasms (2) · Neoplasms (2) · Growth Disorders (1) · Lymphoma (1) · Ovarian Neoplasms (1) · Proteus Infections (1) · Triple Negative Breast Neoplasms (1) · Uterine Cervical Neoplasms (1)
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) (4) · National Human Genome Research Institute (NHGRI) (2) · Merck Sharp & Dohme LLC (1)
United States (6) · Australia (2) · Italy (2) · Brazil (1) · Spain (1) · United Kingdom (1)
PMID 30803705, PMID 33639990, PMID 34649967, PMID 40713644, PMID 42224880
2016 (1)